Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
10.07
-0.03 (-0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,459,096
Open
10.26
Bid (Size)
9.950 (5)
Ask (Size)
10.15 (3)
Prev. Close
10.10
Today's Range
9.995 - 10.51
52wk Range
1.760 - 13.17
Shares Outstanding
50,241,789
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
7 Biotech Stocks to Keep on Your Clinical Radar
July 23, 2024
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.
Via
InvestorPlace
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
July 23, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+193.59%
+193.59%
1 Month
+4.90%
+4.90%
3 Month
+17.23%
+17.23%
6 Month
+108.06%
+108.06%
1 Year
-3.54%
-3.54%
More News
Read More
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
July 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
July 10, 2024
Via
Benzinga
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
April 12, 2024
Via
Benzinga
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
July 10, 2024
Via
Benzinga
Exposures
Product Safety
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 08, 2024
Via
Benzinga
The 7 Best Under $10 Stocks to Buy in July 2024
July 06, 2024
Via
InvestorPlace
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 20, 2024
Via
Benzinga
Have $5-10? 7 Affordable Stocks That Are About to Breakout.
June 13, 2024
Via
InvestorPlace
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 05, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 15, 2024
Via
Benzinga
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
May 15, 2024
Via
Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
May 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 15, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 15, 2024
Via
InvestorPlace
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
May 14, 2024
Via
InvestorPlace
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
May 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
May 14, 2024
Via
Benzinga
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
May 13, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.